無料プレビュー

Dianthus Therapeutics, Inc. (DNTH) · NASDAQ

プロフィール

Dianthus Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins for severe autoimmune diseases. Its lead candidate, claseprubart, is a selective C1s complement inhibitor engineered for extended half-life and infrequent subcutaneous dosing, currently in Phase 2/3 trials for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The company's second candidate, DNTH212, is a bifunctional BDCA2 and BAFF/APRIL inhibitor licensed from Nanjing Leads Biolabs, in early Phase 1 development. D

主要指標

株価: $82.43 (-2.89%)
時価総額: 46億ドル
PER（今期予想）: -21.8
PBR: 3.9
配当利回り: —
52週レンジ: $32.22 – $117.88
業種: Healthcare / Biotechnology
上場: NASDAQ
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09